References
- Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. [cited 2019 Jul 6]; Available at https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2141.2008.07119.x.
- Pastori D, Menichelli D, Gingis R, et al. Tailored practical management of patients with atrial fibrillation: a risk factor-based approach. Front Cardiovasc Med. 2019;6:17.
- Eikelboom JW, Quinlan DJ, Hirsh J, et al. Laboratory monitoring of non–vitamin k antagonist oral anticoagulant use in patients with atrial fibrillation. JAMA Cardiol. 2017;2(5):566.
- Sørensen R, Jamie Nielsen B, Langtved Pallisgaard J, et al. Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists. Eur Hear J Cardiovasc Pharmacother. 2017;3(3):151–156.
- Cataldo N, Pegoraro V, Ripellino C, et al. Non-persistence risk and health care resource utilization of Italian patients with non-valvular atrial fibrillation. Recenti Prog Med. 2018;109:113–121.
- Baker CL, Dhamane AD, Mardekian J, et al. Comparison of drug switching and discontinuation rates in patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants in the United States. Adv Ther. 2019;36(1):162–174.
- Hellfritzsch M, Grove EL, Husted SE, et al. Clinical events preceding switching and discontinuation of oral anticoagulant treatment in patients with atrial fibrillation. Europace. 2016;19:euw241.
- Bouillon K, Bertrand M, Maura G, et al. Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study. Lancet Haematol. 2015;2(4):e150–e159.
- Datar M, Crivera C, Rozjabek H, et al. Comparison of real-world outcomes in patients with nonvalvular atrial fibrillation treated with direct oral anticoagulant agents or warfarin. Am J Heal Pharm. 2019;76(5):275–285.
- Biteker M, Başaran Ö, Doğan V, et al. Real-world clinical characteristics and treatment patterns of individuals aged 80 and older with nonvalvular atrial fibrillation: results from the ReAl-life Multicenter Survey Evaluating Stroke Study. J Am Geriatr Soc. 2017;65(8):1684–1690.
- Cavallari I, Patti G. Efficacy and safety of oral anticoagulation in elderly patients with atrial fibrillation. Anatol J Cardiol. 2018;19:67–71.
- Sabbag A, Yao X, Siontis KC, et al. Anticoagulation for Stroke Prevention in Older Adults with Atrial Fibrillation and Comorbidity: Current Evidence and Treatment Challenges. Korean Circ J. 2018;48(10):873–889.
- Patti G, Pecen L, Lucerna M, et al. Net clinical benefit of non-vitamin K antagonist vs vitamin K antagonist anticoagulants in elderly patients with atrial fibrillation. Am J Med. 2019;132(6):749–757.e5.
- Dhamane AD, Baker CL, Rajpura J, et al. Continuation with apixaban treatment is associated with lower risk for hospitalization and medical costs among elderly patients. Curr Med Res Opin. [cited 2019 Jun 5]; [8 p.]. DOI:10.1080/03007995.2019.1623187
- Steffel J, Verhamme P, Potpara TS, et al. The European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330–1393.